Nimodipine

(R)-limonene 6-monooxygenase, (S)-limonene 6-monooxygenase, (S)-limonene 7-monooxygenase, 1,8-cineole 2-exo-monooxygenase, 2700049B16Rik, 3110031N04Rik, A3AR, A3R, AA3R_HUMAN, ABC member 16, MDR/TAP subfamily, ABC16, ABCB1, ABCBB_HUMAN, AD 026, ADORA 3, AI838772, AIS, ANDR_HUMAN, ANKTM 1, AR, AR JP, AR8, ARA3, ATP binding cassette sub family B (MDR/TAP) member 11, ATP-binding cassette sub-family B member 11, AW493413, Adenosine A3 receptor, Adenosine receptor A3, Albendazole monooxygenase, Albendazole sulfoxidase, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Ankyrin-like with transmembrane domains protein 1, Arachidonic acid epoxygenase, Aryl hydrocarbon hydroxylase, BAR, BK channel, BK channel beta subunit, BK channel subunit beta-1, BK channel subunit beta-2, BK channel subunit beta-4, BKCA alpha, BKCA alpha subunit, BKTM, BKbeta, BKbeta1, BKbeta2, BKbeta4, BRIC2, BXR, Bile acid receptor, Bile salt export pump, Bsep, CAC1C_HUMAN, CACH 2, CACN 2, CACNL1A1, CANN6, CAPC, CB-R, CB1, CB1A, CB1K5, CB1R, CCHL1A1, CNR, CNR1_HUMAN, CP 12, CP1A2_HUMAN, CP2C9_HUMAN, CP2J2_HUMAN, CP33, CP34, CP3A4_HUMAN, CPC12, CPC8, CPC9, CPCJ, CPJ2, CYP1A2, CYP2C, CYP2C10, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIA2, CYPIIC9, CYPIIIA3, CYPIIIA4, CYPIIJ2, CaV1.2, Calcium activated potassium channel beta 4 subunit, Calcium activated potassium channel subfamily M subunit beta 1, Calcium activated potassium channel subfamily M subunit beta 2, Calcium activated potassium channel subfamily M subunit beta 4, Calcium channel, Calcium channel L type alpha 1 polypeptide isoform 1 cardiac muscle, Calcium channel cardic dihydropyridine sensitive alpha 1 subunit, Calcium channel voltage dependent L type alpha 1C subunit, Calcium-activated potassium channel, Calcium-activated potassium channel subunit alpha-1, Calcium-activated potassium channel subunit beta, Calcium-activated potassium channel subunit beta-1, Calcium-activated potassium channel subunit beta-2, Calcium-activated potassium channel subunit beta-4, Cannabinoid receptor 1, Central cannabinoid receptor, Charybdotoxin receptor subunit beta-1, Charybdotoxin receptor subunit beta-2, Charybdotoxin receptor subunit beta-4, Cytochrome P(3)450, Cytochrome P-450MP, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2J2, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 4, Cytochrome P450 HLp, Cytochrome P450 MP-4, Cytochrome P450 MP-8, Cytochrome P450 NF-25, Cytochrome P450 PB-1, Cytochrome P450 family 1 polypeptide 2, Cytochrome P450 family 1 subfamily A polypeptide 2, Cytochrome P450 family 2 subfamily J polypeptide 2, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily I aromatic compound inducible polypeptide 2, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450 subfamily IIJ (arachidonic acid epoxygenase) polypeptide 2, Cytochrome P450 subfamily IIJ polypeptide 2, Cytochrome P450, family 2, subfamily C, polypeptide 9, Cytochrome P450-P3, Cytochrome P450-PCN1, Cytokeratin-associated protein in cancer, DHPR alpha 1, DHPR alpha 1 subunit, DHTR, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), Dioxin inducable P3 450, Drosophila slowpoke like, E3 ubiquitin ligase, E3 ubiquitin-protein ligase parkin, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ESRL 1, ESRR A, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen-related receptor alpha, Estrra, FLJ11090, FRA6E, Farnesoid X-activated receptor, Farnesol receptor HRR-1, GPCR 2, Glucocorticoid inducible P450, HLP, HRR 1, HUMARA, HYSP1, Hbeta1, Hbeta2, Hbeta3, Hbeta4, K(VCA)alpha, K(VCA)beta, K(VCA)beta-1, K(VCA)beta-2, K(VCA)beta-4, KCMA1_HUMAN, KCMB1_HUMAN, KCMB2_HUMAN, KCMB4_HUMAN, KCNMA, KCNMA1, KCNMB 1, KCNMB 2, KCa1.1, KD, Kennedy disease (KD), L type, LPRS 2, LQT8, LRC26_HUMAN, Large conductance Ca2+ activated K+ channel beta 1 subunit, Large conductance Ca2+ activated K+ channel beta2 subunit, Large conductance calcium activated potassium channel beta 2 subunit, Large conductance calcium dependent potassium ion channel beta 4 subunit, Leucine-rich repeat-containing protein 26, Lrrc26, MGC104252, MGC112732, MGC126680, MGC149605, MGC22431, MGC57945, MGC88320, Maxi K channel, Maxi K channel beta subunit, Maxi K channel subunit beta-1, Maxi K channel subunit beta-2, Maxi K channel subunit beta-4, Maxi Potassium channel alpha, MaxiK, MaxiK channel beta 2 subunit, Microsomal monooxygenase, NF 25, NR1I2_HUMAN, NR3B1, NR3C3, NR3C4, Nifedipine oxidase, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 3, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), ONR 1, OTTHUMP00000010550, OTTHUMP00000016838, OTTHUMP00000020135, OTTHUMP00000214579, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P(3)450, P3 450, P450 4, P450 III steroid inducible, P450 MP, P450 P3, P450 PB 1, P450 PCN1, P450 form 4, P450(PA), P450, family III, P450C2C, P450C3, P450IIC19, P450IIC9, PAR, PAR q, PARK 2, PDJ, PFIC 2, PGR, PGY4, PR, PRA, PRB, PRGR_HUMAN, PRKN 2, PRKN2_HUMAN, PRR, Parkin 2, Parkinson disease (autosomal recessive juvenile) 2, Parkinson disease (autosomal recessive, juvenile) 2, parkin, Parkinson disease protein 2, Parkinson juvenile disease protein 2, Parkinson protein 2 E3 ubiquitin protein ligase, Parkinson protein 2, E3 ubiquitin protein ligase (parkin), Potassium large conductance calcium activated channel subfamily M beta member 1, Potassium large conductance calcium activated channel subfamily M beta member 2, Potassium large conductance calcium activated channel subfamily M beta member 4, Pregnane X receptor, Progesterone receptor, Progestin receptor form A, Progestin receptor form B, Quinine 3-monooxygenase, RIP 14, RP11 552M11.7, RP24-311F12.2, RXR-interacting protein 14, Retinoid X receptor-interacting protein 14, S-mephenytoin 4-hydroxylase, SAKCA, SBMA, SCAN1, SLO, SMAX1, SXR, Sister of P glycoprotein, Slo homolog, Slo-alpha, Slo-beta, Slo-beta-1, Slo-beta-2, Slo-beta-4, Slo1, Slowpoke homolog, Spgp, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, Steroid hormone receptor ERR1, TFM, TGPCR1, TRPA1_HUMAN, TS, TYDP, TYDP1_HUMAN, Taurochenodeoxycholate 6-alpha-hydroxylase, Testicular Feminization (TFM), Transformation-sensitive protein p120, Transient receptor potential cation channel subfamily A member 1, Tyr-DNA phosphodiesterase 1, Tyrosyl-DNA phosphodiesterase 1, Ubiquitin E3 ligase PRKN, Voltage dependent L type calcium channel alpha 1C subunit, Voltage gated L type calcium channel Cav1.2 alpha 1 subunit, splice variant 10*, Voltage gated calcium channel alpha subunit Cav1.2, Voltage-dependent L-type calcium channel subunit alpha-1C, Voltage-gated calcium channel subunit alpha Cav1.2, Xenobiotic monooxygenase, alpha-1 polypeptide, androgen receptor splice variant 4b, bA350O14.10, bA552M11.5, cardiac muscle, cytochrome P-450 S-mephenytoin 4-hydroxylase, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, cytokeratin-associated protein, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, hERR1, hSlo, hslo beta, isoform 1, pregnane X nuclear receptor variant 2, progressive familial intrahepatic cholestasis 2, subfamily M subunit alpha-1, subfamily M subunit beta-1, subfamily M subunit beta-2, subfamily M subunit beta-4

Biochemicals